throbber
Downloaded from
`
`http://www.jbc.org/
`
` by guest on July 19, 2019
`
`THE JOURNAL OF BIOLOGICAL CHEMISTRY
`© 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
`
`Vol. 275, No. 46, Issue of November 17, pp. 36197–36203, 2000
`Printed in U.S.A.
`
`Interleukin-11 Signals through the Formation of a Hexameric
`Receptor Complex*
`
`Received for publication, May 30, 2000, and in revised form, August 15, 2000
`Published, JBC Papers in Press, August 17, 2000, DOI 10.1074/jbc.M004648200
`
`Victoria A. Barton‡, Mark A. Hall‡§, Keith R. Hudson¶, and John K. Heathi
`From the Cancer Research Campaign Growth Factor Group, School of Biosciences, University of Birmingham, Edgbaston,
`Birmingham B15 2TT, United Kingdom
`
`Interleukin-11 (IL-11) is a member of the gp130 family
`of cytokines. These cytokines drive the assembly of mul-
`tisubunit receptor complexes, all of which contain at
`least one molecule of the transmembrane signaling re-
`ceptor gp130. IL-11 has been shown to induce gp130-de-
`pendent signaling through the formation of a high affin-
`ity complex with the IL-11 receptor (IL-11R) and gp130.
`Site-directed mutagenesis studies have identified three
`distinct receptor binding sites of IL-11, which enable it
`to form this high affinity receptor complex. Here we
`present data from immunoprecipitation experiments,
`using differentially tagged forms of ligand and soluble
`receptor components, which show that multiple copies
`of IL-11, IL-11R, and gp130 are present in the receptor
`complex. Furthermore, it is demonstrated that sites II
`and III of IL-11 are independent gp130 binding epitopes
`and that both are essential for gp130 dimerization. We
`also show that a stable high affinity complex of IL-11,
`IL-11R, and gp130 can be resolved by nondenaturing
`polyacrylamide gel electrophoresis, and its composition
`verified by second dimension denaturing polyacryl-
`amide gel electrophoresis. Results indicate that the
`three receptor binding sites of IL-11 and the Ig-like do-
`main of gp130 are all essential for this stable receptor
`complex to be formed. We therefore propose that IL-11
`forms a hexameric receptor complex composed of two
`molecules each of IL-11, IL-11R, and gp130.
`
`Interleukin-11 (IL-11)1 is a secreted polypeptide cytokine,
`which has been shown to exhibit in vitro biological effects on a
`diverse range of cell types including hemopoietic cells, hepato-
`cytes, adipocytes, neurons, and osteoblasts (reviewed in Ref. 1).
`
`In vivo administration of IL-11 results in the stimulation of
`megakaryopoeisis and increased platelet counts (2). Recombi-
`nant human IL-11 is now used for the treatment of chemother-
`apy-induced thrombocytopenia (3). IL-11 also has clinical po-
`tential
`for the treatment of several disorders including
`chemotherapy induced oral mucositis (4), Crohn’s disease (5),
`and rheumatoid arthritis (6). Transgenic deletion of the gene
`encoding the specific IL-11 receptor (IL-11R) in mice has revealed
`an important role for IL-11 in embryonic implantation. Female
`mice deficient in the IL-11R are infertile because of defective
`decidualization, following implantation of the embryo (7, 8).
`IL-11 is a member of the gp130 family of cytokines. These
`cytokines drive the assembly of multisubunit receptor com-
`plexes, which initiates intracellular signal transduction path-
`ways. In all cases, the receptor complexes contain at least one
`copy of the signal transducer glycoprotein gp130 (9). Other
`cytokines belonging to this family include interleukin-6 (IL-6),
`leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary
`neurotrophic factor (CNTF), cardiotrophin-1, and a viral homo-
`logue of IL-6 encoded by the Kaposi’s sarcoma-associated her-
`pesvirus. Each of these cytokines exerts its action by either
`homo- or heterodimerization of gp130, which leads to the stim-
`ulation of signaling cascades via protein kinases belonging to
`the Janus kinase, mitogen-activated protein kinase, and Src
`families (10–13).
`The gp130 cytokines exhibit both overlapping and unique
`biological activities in vitro and in vivo (reviewed in Ref. 14).
`The signal exerted by a cytokine and therefore the biological
`response depends on the exact composition of the signaling
`receptor complex. Signaling specificity of the gp130 cytokines is
`conferred by the use of ligand-specific receptors. Specific recep-
`tors for IL-6 (15), IL-11 (16, 17), and CNTF (18) have been
`identified. These receptors are not directly involved in cytoplas-
`mic signaling, but their function is to promote the formation of
`a high affinity complex between the respective ligand and
`gp130. These ligand specific receptors and gp130 are all mem-
`bers of the hemopoietic family of receptors (reviewed in Ref.
`19), characterized by the presence of a cytokine binding homol-
`ogy domain (CHD).
`The CHD, of approximately 200 amino acids, comprises two
`fibronectin type III domains (D1 and D2), with four positionally
`conserved cysteine residues in the first domain and a WSXWS
`motif (where X is any amino acid) in the second domain (20).
`The crystal structure of the CHD of gp130 revealed that the
`two fibronectin type III domains exhibit an approximate L-
`shape (21), and mutagenesis studies have identified residues in
`the hinge region that are important for ligand binding (22–24).
`In addition to the CHD, gp130 and all known receptors that
`bind to the gp130 family of cytokines also contain an amino-
`terminal domain predicted to adopt a seven-b-stranded immu-
`noglobulin-like conformation in their extracellular region (Ig-
`like domain).
`36197
`
`* This work was supported by Cancer Research Campaign grants and
`a Cancer Research Campaign studentship from 1996 to 1999 (to
`V. A. B.). The costs of publication of this article were defrayed in part by
`the payment of page charges. This article must therefore be hereby
`marked “advertisement” in accordance with 18 U.S.C. Section 1734
`solely to indicate this fact.
`‡ These authors contributed equally to this work and should both be
`considered first authors.
`§ Current address: Walter and Elisa Hall Inst. for Medical Research
`and the Rotary Bone Marrow Research Laboratories, Royal Melbourne
`Hospital, Parkville, Victoria, Australia 3050.
`¶ Current address: Genesis Research and Development Corp.,
`Parnell, Auckland, New Zealand.
`i To whom correspondence should be addressed. Tel.: 44-0-121-414-
`7533; Fax: 44-0-121-414-3983; E-mail: j.k.heath@bham.ac.uk.
`1 The abbreviations used are: IL-11, interleukin-11; R, receptor; IL-6,
`interleukin-6; LIF, leukemia inhibitory factor; OSM, oncostatin M;
`CNTF, ciliary neurotrophic factor; CHD, cytokine binding homology
`domain; Ig, immunoglobulin; m (prefix), murine; Fc, constant region of
`human IgG; PCR, polymerase chain reaction; PAGE, polyacrylamide
`gel electrophoresis; BSA, bovine serum albumin; PBS, phosphate-buff-
`ered saline; HRP, horseradish peroxidase; b (prefix), biotinylated; HA,
`hemagglutinin.
`
`This paper is available on line at http://www.jbc.org
`
`Lassen - Exhibit 1006, p. 1
`
`

`

`Downloaded from
`
`http://www.jbc.org/
`
` by guest on July 19, 2019
`
`36198
`
`IL-11 Forms a Hexameric Receptor Complex
`
`The gp130 cytokines share a common four-a-helix bundle
`fold. Crystal structures have been determined for LIF (25),
`CNTF (26), IL-6 (27), and OSM.2 Detailed structural analysis
`and mutagenesis studies of the gp130 family of cytokines have
`revealed clear patterns of receptor engagement (reviewed in
`Ref. 29). It is now apparent that receptor binding epitopes are
`conserved among the gp130 cytokines. Three receptor binding
`sites have been identified for IL-6 (30, 31), IL-11 (32), and
`CNTF (33, 34) (termed sites I, II, and III). Sites I and II are
`analogous to the two receptor binding sites identified for hu-
`man growth hormone (35). In contrast, LIF and OSM have been
`shown to have two binding sites (sites II and III), which enable
`them to form trimeric receptor complexes (36).2 IL-6 is known
`to form a hexameric receptor complex consisting of two mole-
`cules each of IL-6, IL-6R, and gp130 (37, 38).
`IL-11 has been shown to have three distinct receptor binding
`sites analogous in location to sites I, II, and III of IL-6 (32). Site
`I enables IL-11 to bind to IL-11R, while sites II and III both
`mediate binding to gp130. Taken together with the finding that
`IL-11 signaling requires IL-11R and gp130, but not LIF recep-
`tor (LIFR) or OSM receptor (OSMR) (16, 39), it is predicted that
`IL-11 forms a signaling complex in a manner analogous to that
`of IL-6. However, published work regarding the composition
`and stoichiometry of the IL-11 receptor complex has, as yet, not
`been conclusive. Neddermann et al. (40) reported a pentameric
`IL-11 receptor complex consisting of two IL-11, two IL-11R, and
`one gp130. They suggested that gp130 homodimerization is not
`involved in IL-11-mediated signaling and that another, as yet
`unidentified, signaling receptor component is required. Fur-
`thermore, Grotzinger et al. (41) have suggested that the IL-11
`receptor complex may be a tetramer, consisting of one IL-11,
`one IL-11R, and two gp130 molecules (41). Here we report
`findings from in vitro immunoprecipitation experiments and
`gel shift assays, which clearly demonstrate that the IL-11
`receptor complex is a hexamer, consisting of two molecules
`each of IL-11, IL-11R, and gp130.
`
`EXPERIMENTAL PROCEDURES
`Plasmid Constructs—The design and construction of pIG/mIL-11R-
`Fc, pIG/mgp130-Fc, and pGEX/mIL-11 plasmids (IL-11 wild type,
`R111A/L115A, and W147A) has been described previously (32, 39). The
`pIG/mgp130(Ig2)Fc plasmid was derived from pIG/mgp130-Fc (39) by a
`PCR overlap technique. Two DNA fragments upstream and down-
`stream of the region encoding the NH2-terminal Ig-like domain of gp130
`were generated by PCR, using two external primers and two internal
`primers with overlapping ends (the sequences of all primers used are
`available on request). The two DNA fragments were then combined in
`a subsequent PCR reaction with the two external primers, which am-
`plified the fusion product of the two fragments. This fusion product was
`then cloned back into pIG/mgp130-Fc, therefore replacing the region
`encoding the Ig-like domain of gp130.
`pIG/mIL-11R-Myc and pIG/mgp130-Myc, which encode IL-11R and
`gp130 ectodomains with COOH-terminal Myc tags, were derived from
`pIG/mIL-11R-Fc and pIG/mgp130-Fc (39) by subcloning. For both, the
`region encoding the Fc region of human IgG1, bounded by Eco4711 and
`NotI, was replaced with a 401-base pair Eco4711/NotI fragment from
`pIG/mLIFR-poly(Asn)-Myc3 that encodes six Asn residues followed by
`the Myc antibody epitope (EEQKLISEEDL).
`pGEX/HA-IL-11 was constructed as follows. The sequence encoding
`the hemagglutinin (HA) tag (YPYDVPDYA) was added to the 59 end of
`the IL-11 coding region by PCR, using a 59 primer encoding a BamHI
`restriction site and the HA tag, and a 39 primer encoding an EcoRI
`restriction site. The PCR product was then subcloned as a 571-base pair
`BamHI/EcoRI fragment into pGEX-3C (42).
`pCDNA3/IL-11R-HA(3C)Fc was generated by the addition of the HA
`tag coding sequence at the 39 end of IL-11R by PCR. The IL-11R-
`ectodomain coding region was amplified using a 59 primer encoding an
`
`EcoRI restriction site, and a 39 primer encoding the HA tag and a
`BamHI restriction site. The PCR fragment was then subcloned as a
`1137-base pair EcoRI/BamHI fragment into pcDNA3–3C-Fc.4
`Expression and Purification of Proteins—Murine IL-11R-Fc, gp130-
`Fc, gp130(Ig2)Fc, IL-11R-HA-Fc, IL-11R-Myc, and gp130-Myc were ex-
`pressed in human embryonic kidney 293T cells (43) by transient trans-
`fection, as described previously (39). Conditioned media containing Fc
`fusion receptors were then subjected to Protein A affinity chromatog-
`raphy and receptor ectodomains were released by on-column cleavage
`with the human rhinovirus protease 3C (44). Conditioned media con-
`taining Myc-tagged proteins were stored at 220 °C until required.
`IL-11, wild type and mutants, and HA-tagged IL-11 were expressed as
`glutathione S-transferase fusion proteins in Escherichia coli (strain
`JM109). Details of induction, purification using glutathione-Sepharose
`(Amersham Pharmacia Biotech) and cleavage using human rhinovirus
`protease 3C, are as described previously for leukemia inhibitory factor
`(36).
`Proteins were analyzed by SDS-PAGE followed by staining with
`Coomassie Brilliant Blue R250, or Western blotting and detection with
`antisera. For Western blotting, proteins were transferred onto polyvi-
`nylidene difluoride (Millipore) using a standard protocol (45). Mem-
`branes were then blocked overnight in PBS, 3% BSA and subjected to
`immunodetection using antisera diluted in blocking buffer. Blots were
`developed using Super Signal West-Pico enhanced chemiluminescence
`(ECL) (Pierce).
`Biotinylation of Proteins—IL-11 was modified by biotinylation on
`e-amino groups of lysine residues using biotin amidocaproate N-hy-
`droxysuccinimide (Sigma) following a published protocol (32). gp130
`was biotinylated on oxidized oligosaccharides using biotin-hydrazide
`(Pierce) as follows; gp130 was first buffer-exchanged into phosphate/
`EDTA buffer (100 mM sodium phosphate, pH 6.0, 5 mM EDTA) and
`treated with 20 mM sodium m-periodate for 20 min at 4 °C in the dark.
`gp130 was then buffer exchanged into fresh phosphate/EDTA buffer
`and reacted with an equimolar quantity of biotin-hydrazide for 16–18 h
`at 4 °C. Dialysis against PBS was carried out to remove unbound biotin.
`Biotinylated proteins were examined by SDS-PAGE followed by West-
`ern blotting and detection with streptavidin-HRP conjugate (Amer-
`sham Pharmacia Biotech) and ECL.
`Co-immunoprecipitation of Differentially Tagged Cytokine-Receptor
`Complexes—Slightly different strategies were adopted for co-immuno-
`precipitation of the different components of the IL-11 receptor complex.
`For immunoprecipitation of bIL-11zHA-IL-11 complexes, equimolar con-
`centrations (100 nM) of HA-IL-11, bIL-11, gp130, and IL-11R were
`mixed together in various combinations, in a total volume of 500 ml of
`binding buffer (PBS, 1% BSA, 0.05% Tween 20). Mixtures were incu-
`bated for 3 h atroom temperature at which point, NeutrAvidin-agarose
`(Pierce) (10 ml) was added and then agitated for 16–18 h at 4 °C.
`For immunoprecipitation of complexes containing Myc-tagged com-
`ponents, 5 ml of anti-Myc monoclonal antibody (clone 9E10, BABCo) was
`first immobilized on 8 ml of Protein G-Sepharose (Amersham Pharma-
`cia Biotech), in a final volume of 500 ml of binding buffer. The resin was
`then used to immunoprecipitate gp130-Myc from 500 ml of 293T condi-
`tioned medium. This “loaded” resin was then added to 500 ml of binding
`buffer containing equimolar concentrations (100 nM) of IL-11, IL-11R,
`and bgp130, in various combinations, and incubated for 16–18 h at 4 °C
`with agitation. Similarly, IL-11R-Myc was immunoprecpitated using
`resin coated with anti-Myc monoclonal antibody and then added to 500
`ml of binding buffer containing equimolar concentrations (100 nM) of
`IL-11, IL-11R-HA, and gp130 or bgp130, in various combinations, and
`incubated for 16–18 h at 4 °C with agitation.
`Following all immunoprecipitation reactions, complexes were har-
`vested by centrifugation, extensively washed with PBS, 0.1% Tween 20,
`and resuspended in 20 ml of SDS-PAGE loading buffer (300 mM Tris, pH
`6.8, 600 mM dithiothreitol, 12% SDS, 0.6% bromphenol blue, 30% glyc-
`erol). The immunoprecipitated proteins were then resolved by SDS-
`PAGE, Western-blotted, and detected using a mouse anti-HA mono-
`clonal antibody (clone 12CA5, Roche Molecular Biochemicals) or
`streptavidin-HRP conjugate, followed by ECL.
`Nondenaturing PAGE and Second Dimension Denaturing PAGE—
`Equimolar concentrations of IL-11 and soluble receptor components
`were mixed together, in various combinations, in a total volume of 16 ml
`of PBS, 0.05% Tween 20. Complexes were allowed to form for a mini-
`mum of 4 h at 18–22 °C. 4 ml of native gel loading buffer (120 mM Tris,
`pH 6.8, 745 mM glycine, 50% glycerol, 0.5% bromphenol blue) was then
`added and each sample loaded onto a 4–20% Tris-glycine gel (Novex).
`
`2 Deller, M. C., Hudson, K. R., Ikemizu, S., Bravo, J., Jones, F. Y., and
`Heath, J. K. (2000) Structure 8, 863–874.
`3 K. R. Hudson, unpublished data.
`
`4 M. A. Hall, unpublished data.
`
`Lassen - Exhibit 1006, p. 2
`
`

`

`IL-11 Forms a Hexameric Receptor Complex
`
`36199
`
`Downloaded from
`
`http://www.jbc.org/
`
` by guest on July 19, 2019
`
`FIG. 1. Immunoprecipitation of gp130-Myc complexes. gp130-
`Myc was immobilized on resin and incubated with combinations of
`bgp130, IL-11, and IL-11R (100 nM amounts of each). After incubation
`and washing, bound components were analyzed by SDS-PAGE, followed
`by Western blotting. Detection was carried out using streptavidin-HRP
`conjugate (diluted 1 in 4,000) and ECL.
`
`Electrophoresis was then carried out at 15 mA for 2 h innative running
`buffer (24 mM Tris, 149 mM glycine). Proteins were detected using either
`Coomassie Brilliant Blue R250 or silver staining (46).
`For second dimension SDS-PAGE, Coomassie-stained bands were
`excised from the gel and soaked in SDS loading buffer (62.5 mM Tris, pH
`6.8, 5% 2-mercaptoethanol, 2% SDS, 0.1% bromphenol blue, 10% glyc-
`erol) for 5 min. The proteins were then resolved by SDS-PAGE using a
`12% polyacrylamide gel and detected by silver staining (46).
`
`RESULTS
`Multiple Copies of gp130, IL-11R, and IL-11 Are Present in
`the IL-11 Receptor Complex—IL-11-mediated signaling has
`been shown to require both IL-11R and gp130 (16, 32, 39). A
`specific interaction between IL-11 and the IL-11R has been
`demonstrated, and a soluble form of IL-11R has been shown to
`promote the formation of a high affinity complex between IL-11
`and gp130 (39). To assess the stoichiometry of this high affinity
`IL-11 receptor complex immunoprecipitation experiments us-
`ing differentially tagged receptor components, similar to the
`assays used by Paonessa et al. (38), were carried out. Each
`component of the receptor complex was labeled with two dif-
`ferent tags. Receptor complexes were then immunoprecipitated
`using one tag and examined by Western blot analysis to deter-
`mine whether the second tag could be detected. The ability to
`co-precipitate differentially tagged forms of a protein indicated
`the presence of two copies of that protein in the receptor
`complex.
`To examine the number of gp130 molecules in the IL-11
`receptor complex, Myc-tagged gp130 was first immobilized on
`Sepharose beads coated with anti-Myc monoclonal antibody.
`Immunoprecipitations were then carried out using various
`combinations of
`IL-11,
`IL-11R, and biotinylated gp130
`(bgp130). Following SDS-PAGE and Western blotting, immu-
`noprecipitated bgp130 was detected using streptavidin-HRP
`conjugate. The results, as shown in Fig. 1, indicate that bgp130
`(which migrates with an approximate molecular mass of 97
`kDa) was co-precipitated with gp130-Myc, in the presence of
`IL-11 and IL-11R (see lane 1). In the absence of either IL-11R
`or IL-11, immunoprecipitated bgp130 could not be detected (see
`lanes 2 and 4). These results show that at least two copies of
`gp130 are present in the IL-11 receptor complex and that both
`IL-11 and IL-11R are required for gp130 dimerization.
`A similar approach, using Myc-tagged IL-11R and HA-
`tagged IL-11R, was used to investigate the number of IL-11R
`molecules present in the IL-11 receptor complex. Following
`immunoprecipitations, using immobilized IL-11R-Myc and var-
`ious combinations of IL-11, gp130, and IL-11R-HA, the pres-
`ence of the latter was detected using anti-HA antiserum. The
`
`FIG. 2. Immunoprecipitation of IL-11R-Myc complexes. IL-11R-
`Myc was immobilized on resin and incubated with combinations of
`IL-11R-HA, gp130, and IL-11 (100 nM amounts of each). After incuba-
`tion and washing, bound components were analyzed by SDS-PAGE
`followed by Western blotting. Detection was carried out using a bioti-
`nylated anti-HA monoclonal antibody (diluted 1 in 5,000) followed by
`streptavidin-HRP conjugate (diluted 1 in 5,000) and ECL.
`
`FIG. 3. Immunoprecipitation of bIL-11 complexes. Combina-
`tions of bIL-11, HA-IL-11, IL-11R, and gp130 were mixed together and
`incubated (100 nM amounts of each). Complexes were then immunopre-
`cipitated using NeutrAvidin-agarose. After washing, bound components
`were analyzed by SDS-PAGE followed by Western blotting. Detection
`was carried out using an anti-HA monoclonal antibody (diluted 1 in
`5,000), followed by sheep anti-mouse HRP conjugate (diluted 1 in 5,000)
`and ECL.
`
`results, as shown in Fig. 2, show that IL-11R-HA (which mi-
`grates with an approximate molecular mass of 45 kDa) was
`co-precipitated with IL-11R-Myc, but only in the presence of
`both IL-11 and gp130 (see lane 3). This indicates that the high
`affinity IL-11 receptor complex contains at least two copies of
`IL-11R.
`To examine the number of IL-11 molecules in the IL-11
`receptor complex, biotinylated IL-11 (bIL-11) was first immo-
`bilized on NeutrAvidin-agarose. Immunoprecipitations were
`then carried out using various combinations of IL-11R, gp130,
`and HA-tagged IL-11. The presence of HA-IL-11 in the immu-
`noprecipitates was detected using anti-HA antiserum. The re-
`sults, as shown in Fig. 3, show that HA-IL-11 (which migrates
`with an approximate molecular mass of 22 kDa) was co-precip-
`itated with bIL-11, but only in the presence of both IL-11R and
`gp130 (see lane 1). This indicates that at least two copies of
`IL-11 are present in the high affinity IL-11 receptor complex.
`The complex thus contains multiple copies of IL-11, IL-11R,
`and gp130.
`IL-11 Site II and Site III Mutants Are Unable to Dimerize
`gp130—Immunoprecipitation experiments, similar to those de-
`
`Lassen - Exhibit 1006, p. 3
`
`

`

`36200
`
`IL-11 Forms a Hexameric Receptor Complex
`
`Downloaded from
`
`http://www.jbc.org/
`
` by guest on July 19, 2019
`
`FIG. 4. Immunoprecipitation of gp130-Myc and IL-11R-Myc
`complexes formed by IL-11 mutants. A, gp130-Myc was immobi-
`lized on resin and incubated with combinations of bgp130, IL-11R, and
`bIL-11 (100 nM amounts of each). B, IL-11R-Myc was immobilized on
`resin and incubated with combinations of bgp130 and bIL-11 (100 nM
`amounts of each). WT represents wild type, while D2 and D3 represent
`the site II mutant R111A/L115A and the site III mutant W147A, re-
`spectively. After incubation and washing, bound components were an-
`alyzed by SDS-PAGE followed by Western blotting. Detection was car-
`ried out using streptavidin-HRP conjugate (diluted 1 in 4,000) and ECL.
`
`scribed above, were also used to examine the ability of IL-11
`mutants to form high affinity receptor complexes. It has previ-
`ously been shown that both the site II mutant, R111A/L115A,
`and the site III mutant, W147A, exhibit reduced binding to
`gp130 and hence reduced biological activity, while maintaining
`normal affinity for IL-11R (32). Immunoprecipitation assays
`were performed using immobilized gp130-Myc and various
`combinations of bgp130, IL-11R, and wild type or mutant bIL-
`11. By using both biotinylated ligand and bgp130, this enabled
`us to examine the ability of the IL-11 mutants to bind to
`gp130-Myc in the presence of IL-11R, and also the ability of the
`mutants to co-precipitate bgp130. The results, as shown in Fig.
`4A, confirm those described earlier, i.e. bgp130 is only co-
`precipitated with gp130-Myc in the presence of IL-11R and wild
`type IL-11 (see lane 1). Neither the site II mutant, R111A/
`L115A, nor the site III mutant, W147A, were able to dimerize
`gp130, as bgp130 was not co-precipitated with gp130-Myc in
`the presence of IL-11R (Fig. 4A, see lanes 5 and 6). However,
`the fact that biotinylated mutant ligand was detected (see lanes
`5 and 6) indicates that both of the IL-11 mutants were co-
`precipitated with gp130-Myc, in the presence of IL-11R, even
`though a second molecule of gp130 was not detected.
`These results provide evidence that sites II and III of IL-11
`are independent gp130 binding sites and that both sites are
`
`FIG. 5. Nondenaturing PAGE and second dimension SDS-
`PAGE of IL-11 receptor complex. A, native PAGE. Equimolar con-
`centrations (1 mM) of IL-11, IL-11R, and gp130 were mixed together in
`various combinations. After incubation, complexes were subjected to
`nondenaturing PAGE. Proteins were detected using Coomassie stain.
`B, SDS-PAGE. Bands 1* and 2* (see Fig. 5A) were excised from the
`Coomassie-stained gel, soaked in SDS loading buffer, and subjected to
`SDS-PAGE. Proteins were detected by silver staining.
`
`required for the dimerization of gp130. The results suggest that
`both the site II mutant and the site III mutant, although
`unable to dimerize gp130, can bind a single molecule of gp130
`in the presence of IL-11R. This was confirmed by the co-pre-
`cipitation of bgp130 with IL-11R-Myc by the two mutants, as
`shown in Fig. 4B. These results indicate that mutation of one
`gp130 binding site (either site II or site III) does not affect the
`other gp130 binding site, which remains free and intact to bind
`a single molecule of gp130. If IL-11 binds to IL-11R with a 1:1
`stoichiometry, this indicates that the two mutants formed tri-
`meric complexes, consisting of one molecule each of IL-11,
`IL-11R, and gp130.
`A Stable Complex of IL-11, IL-11R, and gp130 Can Be Re-
`solved by Nondenaturing PAGE—The results described above,
`together with the fact that a complex of IL-11 and soluble
`IL-11R can mediate signaling by association with gp130 (39),
`suggest that interactions between IL-11 and the extracellular
`regions of gp130 and IL-11R are sufficient for the formation of
`a high affinity receptor complex. A stable complex formed be-
`tween IL-11 and soluble forms of IL-11R and gp130 can be
`resolved by nondenaturing PAGE. Equimolar quantities (1 mM)
`of IL-11, soluble IL-11R, and soluble gp130 were mixed to-
`gether in various combinations, incubated to allow complexes
`to form, and subjected to nondenaturing PAGE. The results, as
`shown in Fig. 5A, show that a complex of IL-11, IL-11R, and
`gp130 can be resolved as a discrete band (see lane 1), which was
`not be detected if any one of the three components was absent.
`IL-11R and gp130 alone were detected as single bands follow-
`ing nondenaturing PAGE, as indicated in Fig. 5A. Free IL-11
`does not migrate into the gel, because of its high isoelectric
`
`Lassen - Exhibit 1006, p. 4
`
`

`

`IL-11 Forms a Hexameric Receptor Complex
`
`36201
`
`Downloaded from
`
`http://www.jbc.org/
`
` by guest on July 19, 2019
`
`FIG. 6. Nondenaturing PAGE of receptor complexes formed by
`IL-11 mutants. Equimolar concentrations (300 nM) of IL-11, IL-11R,
`and gp130 were mixed together in various combinations. WT represents
`wild type, while D2 and D3 represent the site II mutant R111A/L115A
`and the site III mutant W147A, respectively. After incubation, com-
`plexes were subjected to nondenaturing PAGE and detection was car-
`ried out using silver staining (46).
`
`value (predicted to be 11.7). A complex of IL-11 and IL-11R was
`also detected as a faint band, which had migrated further into
`the gel compared with the IL-11zIL-11Rzgp130 complex (see
`Fig. 5A, lane 2). However, this IL-11zIL-11R complex was only
`observed if high concentrations (1 mM) of recombinant protein
`were used. If lower concentrations (in the nanomolar range) of
`recombinant protein were used, only the high affinity IL-11zIL-
`11Rzgp130 complex could be detected (see Fig. 6). This is prob-
`ably because complexes of IL-11 and IL-11R dissociate more
`easily compared with ternary complexes containing IL-11, IL-
`11R, and gp130. IL-11 has been previously shown to bind gp130
`in the presence of IL-11R with higher affinity compared with
`binding IL-11R alone (16, 39).
`The high affinity complex resolved by nondenaturing PAGE
`(labeled as band 1* in Fig. 5A) was predicted to contain IL-11,
`IL-11R, and gp130 because in the absence of either one of the
`components it could not be detected. The composition of the
`complex was confirmed by second dimension SDS-PAGE. The
`results, as shown in Fig. 5B, indicate that IL-11, IL-11R, and
`gp130 were all present in the ternary complex, which resolved
`as a discrete band during nondenaturing PAGE. Similarly, the
`composition of the IL-11zIL-11R complex (labeled as band 2* in
`Fig. 5A) was confirmed using this method (see Fig. 5B).
`IL-11 Site II and Site III Mutants Are Unable to Form a
`Stable Ternary Receptor Complex—To further investigate the
`stoichiometry of the ternary receptor complex, observed as a
`discrete band following nondenaturing PAGE, the ability of
`IL-11 mutants to form such a complex was examined. The
`results described earlier indicate that the site II mutant,
`R111A/L115A, and the site III mutant, W147A, are both unable
`to dimerize gp130, although they can bind a single molecule of
`gp130 in the presence of IL-11R. The ability of these two
`mutants to form a stable receptor complex was therefore ex-
`amined using nondenaturing PAGE. Equimolar concentrations
`(300 nM) of IL-11, IL-11R, and gp130 were mixed together,
`incubated, and subjected to nondenaturing PAGE. Receptor
`complexes were then visualized using silver staining (46). The
`results, as shown in Fig. 6, were consistent with those de-
`scribed above, i.e. a complex of IL-11 wild type, IL-11R, and
`gp130 was observed as a single discrete band (see lane 1),
`which could not be detected if either IL-11R or gp130 were
`absent. A complex of IL-11 and IL-11R was not detectable using
`these concentrations of recombinant protein (300 nM).
`The results in Fig. 6 also show that both the site II mutant,
`R111A/L115A, and the site III mutant, W147A, were unable to
`efficiently form a stable receptor complex co-migrating with
`that of IL-11 wild type. The receptor complexes formed by the
`site II mutant (see lane 5) include a very faint band co-migrat-
`
`FIG. 7. Nondenaturing PAGE of IL-11 receptor complexes
`formed by an Ig deletion mutant of gp130. Equimolar concentra-
`tions (300 nM) of IL-11, IL-11R, and gp130 or gp130(Ig2) were mixed
`together in various combinations. After incubation, complexes were
`subjected to nondenaturing PAGE and detection was carried out using
`silver staining (46).
`
`ing with the ternary complex formed by IL-11 wild type, but
`also a second complex, which has migrated further into the gel.
`This second complex appears to co-migrate with a dimer of
`IL-11 R111A/L115A and IL-11R, observed in lane 6. However,
`the intensity of the band is stronger in the presence of gp130
`(compare lanes 5 and 6), which, together with the earlier re-
`sults from immunoprecipitation experiments, indicate that this
`band is a trimer. The fact that a dimer of IL-11 R111A/L115A
`and IL-11R was detected, while a dimer of IL-11 wild type and
`IL-11R was not detectable, correlates with the fact that the site
`II mutant has a 4-fold increase in affinity for IL-11R compared
`with IL-11 wild type, as described previously (32). The results
`in Fig. 6 also show that the site III mutant, W147A, was unable
`to form a stable receptor complex co-migrating with that of
`IL-11 wild type during nondenaturing PAGE. Instead, a single
`band that migrated further into the gel was detected (see lane
`7). This band was not detected in the absence of gp130 (see lane
`8), which suggests that it represents a trimeric receptor com-
`plex, as opposed to a dimer of IL-11 W147A and IL-11R.
`The results described here from nondenaturing PAGE, and
`the immunoprecipitation experiments described earlier, sug-
`gest that the single discrete band formed by IL-11 wild type,
`IL-11R, and gp130 (as seen in lanes 1 of Figs. 5A and 6)
`represents a hexamer. Trimeric receptor complexes can also be
`detected as single bands although they co-migrate with dimers
`of IL-11zIL-11R and, like the dimers, they appear to be less
`stable than the hexamer. The fact that the site II mutant
`exhibited a significant reduction in its ability to form a hex-
`amer, compared with IL-11 wild type (i.e small amounts of
`hexamer were detected), while the site III mutant was unable
`to form a hexamer correlates with the observed biological ac-
`tivities of these two mutants. That is, R111A/L115A shows
`more than a 10-fold reduction in biological activity, compared
`with IL-11 wild type, while the activity of W147A is completely
`abolished, as described previously (32).
`The Ig-like Domain of gp130 Is Required for a Stable Ternary
`Complex of IL-11, IL-11R, and gp130 to Be Formed—The abil-
`ity of a gp130 mutant, lacking the Ig-like domain, to form a
`stable receptor complex was also examined using nondenatur-
`ing PAGE. Various combinations of IL-11 wild type, IL-11R,
`and either wild type or the Ig deletion mutant of gp130 were
`mixed together, incubated, and subjected to nondenaturing
`PAGE. Receptor complexes were then visualized using silver
`staining (46). The results, as shown in Fig. 7, show that a
`complex of IL-11, IL-11R, and the Ig deletion mutant of gp130
`was detectable as a band, which migrated further into the gel,
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket